 "What ‘unbelievable demand’ for weight-loss drugs adds up to for maker Lilly – Firstpost")
Increased manufacturing capacity for Eli Lilly’s highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion on Thursday, and its share jumped as much as 14 per cent. Lilly also raised its 2024 profit forecast and said sales of Zepbound crossed $1 billion for the first time … Read more
About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. Mercer also said 64% of U.S. employers with over 20,000 employees covered weight-loss drugs in 2024, compared with 56% last year. That … Read more
Eli Lilly offers discounted Zepbound vials at half the usual monthly cost – CBS News Watch CBS News Eli Lilly says it will sell one-dose vials of Zepbound for roughly half the usual monthly list price. The weight loss drug, also known as Mounjaro, can cost more than $1,000 for one month’s supply. CBS News … Read more
Former hedge fund manager and host of the CNBC show “Mad Money,” Jim Cramer, strives to help people think like professional investors and, in early July, named several companies that can reach a market capitalisation of $1 trillion. Cramer nominated pharma giant (1) Eli Lilly (NYSE: LLY) and (2) EV maker Tesla (NASDAQ: TSLA) as … Read more
